Literature DB >> 10608623

Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa.

M A Miller1, J Wenger, N Rosenstein, B Perkins.   

Abstract

BACKGROUND: Although the meningococcal polysaccharide vaccine has contributed to the control of Group A meningitis in the "meningitis belt" of Africa, recurrent large outbreaks have led to questions regarding vaccination strategy. We evaluated current and hypothetical vaccination strategies for the region.
METHODS: A model was formulated to analyze the effectiveness and costs of vaccine campaigns in response to outbreaks based on 7 years of weekly incidence data from Burkina Faso. Additional models analyzed the potential impact and costs of either a 1- or 4-dose routine scheduled delivery of meningococcal polysaccharide vaccine based on data reported to the World Health Organization from 16 countries during 1948 through 1996. Vaccine efficacy, vaccination coverage and economic data from literature reviews provided model assumptions.
RESULTS: For Burkina Faso neither 1- nor 4-dose vaccination schedules would prevent >30% of meningitis cases compared with the 42% prevented through an outbreak response program of vaccinating districts, which reach an incidence of 15 per 100000 persons for 2 weeks. For the entire meningitis belt, routine coverage with the 1- or 4-dose schedule meningococcal vaccine would require 4.9 and 19.6 million doses annually, respectively, for an annual net cost of $4.4 to $12.3 million and prevent an average 10300 to 12600 cases (23 to 28%), assuming a long term vaccine efficacy of 50%. In addition an initial "catch-up" campaign costing up to $72 million to vaccinate the population from 1 to 30 years of age would be required before achieving that level of effectiveness.
CONCLUSION: Given the relatively poor routine vaccination coverage in this region, current strategies of vaccination campaigns that achieve higher coverage would generally be more effective and less costly than the modeled routine scheduled programs, assuming that campaigns can be rapidly implemented. Until a better vaccine is available, countries in this region would be more efficient in improving the response times to outbreaks, perhaps through improved surveillance, and in bolstering existing vaccination infrastructures rather than embarking on strategies of questionable effectiveness.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608623     DOI: 10.1097/00006454-199912000-00005

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  11 in total

1.  A Bayesian network approach to the study of historical epidemiological databases: modelling meningitis outbreaks in the Niger.

Authors:  A Beresniak; E Bertherat; W Perea; G Soga; R Souley; D Dupont; S Hugonnet
Journal:  Bull World Health Organ       Date:  2012-01-20       Impact factor: 9.408

Review 2.  Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis.

Authors:  Mark A Miller; Cathryn K Shahab
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

4.  Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa.

Authors:  P T Beernink; D A Caugant; J A Welsch; O Koeberling; D M Granoff
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

5.  Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.

Authors:  Rolando Pajon; Andrew M Fergus; Oliver Koeberling; Dominique A Caugant; Dan M Granoff
Journal:  PLoS Negl Trop Dis       Date:  2011-09-06

6.  Meningococcal conjugate vaccines: optimizing global impact.

Authors:  Andrew Terranella; Amanda Cohn; Thomas Clark
Journal:  Infect Drug Resist       Date:  2011-09-21       Impact factor: 4.003

Review 7.  Comparative study of meningitis dynamics across nine African countries: a global perspective.

Authors:  Hélène Broutin; Solenne Philippon; Guillaume Constantin de Magny; Marie-Françoise Courel; Benjamin Sultan; Jean-François Guégan
Journal:  Int J Health Geogr       Date:  2007-07-10       Impact factor: 3.918

Review 8.  From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.

Authors:  M Teresa Aguado; Luis Jodar; Dan Granoff; Regina Rabinovich; Costante Ceccarini; Gordon W Perkin
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

Review 9.  Global practices of meningococcal vaccine use and impact on invasive disease.

Authors:  Asad Ali; Rabab Zehra Jafri; Nancy Messonnier; Carol Tevi-Benissan; David Durrheim; Juhani Eskola; Florence Fermon; Keith P Klugman; Mary Ramsay; Samba Sow; Shao Zhujun; Zulfiqar Bhutta; Jon Abramson
Journal:  Pathog Glob Health       Date:  2014-01       Impact factor: 2.894

10.  Serogroup W-135 meningococcal disease during the Hajj, 2000.

Authors:  Jairam R Lingappa; Abdullah M Al-Rabeah; Rana Hajjeh; Tajammal Mustafa; Adel Fatani; Tami Al-Bassam; Amira Badukhan; Abdulhafiz Turkistani; Sahar Makki; Nassen Al-Hamdan; Mohamed Al-Jeffri; Yaqoub Al Mazrou; Bradley A Perkins; Tonja Popovic; Leonard W Mayer; Nancy E Rosenstein
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.